Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.
Drugs
Medical
Pharma